Nexalin Technology (NXL) Net Equity Issued and Repurchased (2021 - 2026)

Nexalin Technology's (NXL) quarterly Net Equity Issued and Repurchased came in at $756000.0 in Q1 2026, down 91.15% quarter-over-quarter from $8.5 million in Q3 2022.

Nexalin Technology (NXL) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends

Nexalin Technology's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $756000.0 for Q1 2026.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $756000.0 in Q1 2026; TTM through Mar 2026 was $756000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $4.6 million, up 2.88% from the prior year.
  • Net Equity Issued and Repurchased declined to $756000.0 in Q1 2026 per NXL's latest filing, from $8.5 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $8.5 million in Q3 2022 and bottomed at $5100.0 in Q1 2022.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 97.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 12.70 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Nexalin Technology 9.32 Mn 6.61 Mn 13,133.00 756,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 756,000.00
Mar 31, 2026 756,000.00
Sep 30, 2022 8.54 Mn
Sep 30, 2022 8.54 Mn
Mar 31, 2022 5,100.00
Mar 31, 2022 5,100.00
Dec 31, 2021 762,360.00
Dec 31, 2021 762,360.00